Sales of Trelegy Ellipta and Flixotide/Flovent surged 17% and 47%, respectively. Sales of Advair/Seretide and Anoro Ellipta fell 2% each. Revlar/Breo Ellipta sales declined 5%. The decline in ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler prescribed for COPD and asthma. Trelegy Ellipta has interactions with some other drugs ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

They include Trelegy Ellipta (asthma, COPD) and three big-name drugs for weight loss, diabetes and heart disease: Rybelsus, Ozempic and Wegovy. These negotiations would have to be implemented by ...

They include Trelegy Ellipta (asthma, COPD) and three big-name drugs for weight loss, diabetes and heart disease: Rybelsus, Ozempic and Wegovy. These negotiations would have to be implemented by ...

They include Trelegy Ellipta (asthma, COPD) and three big-name drugs for weight loss, diabetes and heart disease: Rybelsus, Ozempic and Wegovy. These negotiations would have to be implemented by ...

Medicare will continue to negotiate drug prices in 2025. (HealthDay News) — Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and ...